- Home
- AIFU vs SNSE Comparison
AIFU vs SNSE Comparison
Compare AIFU & SNSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIFU
- SNSE
- Stock Information
- Founded
- AIFU 1998
- SNSE 2005
- Country
- AIFU China
- SNSE United States
- Employees
- AIFU N/A
- SNSE N/A
- Industry
- AIFU
- SNSE Biotechnology: Pharmaceutical Preparations
- Sector
- AIFU
- SNSE Health Care
- Exchange
- AIFU NYSE
- SNSE Nasdaq
- Market Cap
- AIFU 11.9M
- SNSE 12.5M
- IPO Year
- AIFU 2007
- SNSE 2021
- Fundamental
- Price
- AIFU $0.21
- SNSE $0.37
- Analyst Decision
- AIFU
- SNSE Strong Buy
- Analyst Count
- AIFU 0
- SNSE 4
- Target Price
- AIFU N/A
- SNSE $4.25
- AVG Volume (30 Days)
- AIFU 568.0K
- SNSE 8.1M
- Earning Date
- AIFU 04-15-2025
- SNSE 03-28-2025
- Dividend Yield
- AIFU N/A
- SNSE N/A
- EPS Growth
- AIFU N/A
- SNSE N/A
- EPS
- AIFU 0.38
- SNSE N/A
- Revenue
- AIFU $324,923,970.00
- SNSE N/A
- Revenue This Year
- AIFU N/A
- SNSE N/A
- Revenue Next Year
- AIFU $11.81
- SNSE N/A
- P/E Ratio
- AIFU $0.55
- SNSE N/A
- Revenue Growth
- AIFU N/A
- SNSE N/A
- 52 Week Low
- AIFU $0.20
- SNSE $0.25
- 52 Week High
- AIFU $4.87
- SNSE $1.94
- Technical
- Relative Strength Index (RSI)
- AIFU N/A
- SNSE 38.86
- Support Level
- AIFU N/A
- SNSE $0.25
- Resistance Level
- AIFU N/A
- SNSE $0.76
- Average True Range (ATR)
- AIFU 0.00
- SNSE 0.07
- MACD
- AIFU 0.00
- SNSE -0.01
- Stochastic Oscillator
- AIFU 0.00
- SNSE 22.75
About AIFU FANHUA INC SPON ADS EACH REPR 20 ORD SHS
AIX Inc is a technology-driven financial services provider company in China. It is an intelligent platform that creates a supportive and collaborative environment and provides solutions that integrate technology, products, services, operations, capital, and professional support for individual agents and sales organizations. The group uses technology, AI, and data-driven insights, pioneering the financial services that are delivered, its transformation, and empowering industry development. It connects customers with financial institutions, investment opportunities, and service providers, offering insurance, wealth management, and other value-added services.
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing highly selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101, SNS-102, SNS-103, SNS-20.